Literature DB >> 33273140

First COVID-19 molecular docking with a chalcone-based compound: synthesis, single-crystal structure and Hirshfeld surface analysis study.

Mona A Alsafi1, David L Hughes2, Musa A Said1.   

Abstract

The first example of molecular docking of the SARS-CoV-2 main protease for COVID-19 [Mpro, Protein Data Bank (PDB) code 7BQY] by a chalcone-based ligand, namely, (E)-1-(2,4-dichlorophenyl)-3-[4-(morpholin-4-yl)phenyl]prop-2-en-1-one, C19H17Cl2NO2, I, is presented. Two-dimensional (2D) LIGPLOT representations calculated for the inhibitor N3, viz. N-{[(5-methylisoxazol-3-yl)carbonyl]alanyl}-L-valyl-N1-((1R,2Z)-4-(benzyloxy)-4-oxo-1-{[(3R)-2-oxopyrrolidin-3-yl]methyl}but-2-enyl)-L-leucinamide, and 7BQY are included for comparison with our chalcone-based complexes. The binding affinity of our chalcone ligand with 7BQY is -7.0 kcal mol-1, a high value which was attributed to the presence of a hydrogen bond, together with many hydrophobic interactions between the drug and the active amino acid residues of the receptor. Docking studies were also performed, employing rigid and flexible binding modes for the ligand. The superposition of N3 and the chalcone docked into the binding pocket of 7BQY is also presented. The synthesis, single-crystal structure, Hirshfeld surface analysis (HSA) and spectral characterization of heterocyclic chalcone-based compound I, are also presented. The molecules are stacked, with normal π-π interactions, in the crystal.

Entities:  

Keywords:  COVID-19; Hirshfeld surface analysis (HSA); chalcone; crystal structure; in silico molecular docking; main protease

Year:  2020        PMID: 33273140     DOI: 10.1107/S2053229620014217

Source DB:  PubMed          Journal:  Acta Crystallogr C Struct Chem        ISSN: 2053-2296            Impact factor:   1.172


  7 in total

1.  Synthesis and greener pastures biological study of bis-thiadiazoles as potential Covid-19 drug candidates.

Authors:  Musa A Said; Sayed M Riyadh; Nadia S Al-Kaff; A A Nayl; Khaled D Khalil; Stefan Bräse; Sobhi M Gomha
Journal:  Arab J Chem       Date:  2022-07-11       Impact factor: 6.212

2.  A possible potential COVID-19 drug candidate: Diethyl 2-(2-(2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)acetyl)hydrazono)malonate: Docking of disordered independent molecules of a novel crystal structure, HSA/DFT/XRD and cytotoxicity.

Authors:  Mohcine Missioui; Musa A Said; Güneş Demirtaş; Joel T Mague; Ahlam Al-Sulami; Nadia S Al-Kaff; Youssef Ramli
Journal:  Arab J Chem       Date:  2021-11-28       Impact factor: 5.165

Review 3.  Can anti-parasitic drugs help control COVID-19?

Authors:  Yasin Panahi; Masoomeh Dadkhah; Sahand Talei; Zahra Gharari; Vahid Asghariazar; Arash Abdolmaleki; Somayeh Matin; Soheila Molaei
Journal:  Future Virol       Date:  2022-03-18       Impact factor: 1.831

Review 4.  Synthesis of Chalcones Derivatives and Their Biological Activities: A Review.

Authors:  Nadia A A Elkanzi; Hajer Hrichi; Ruba A Alolayan; Wassila Derafa; Fatin M Zahou; Rania B Bakr
Journal:  ACS Omega       Date:  2022-08-02

5.  Virtual screenings of the bioactive constituents of tea, prickly chaff, catechu, lemon, black pepper, and synthetic compounds with the main protease (Mpro) and human angiotensin-converting enzyme 2 (ACE 2) of SARS-CoV-2.

Authors:  Nazim Uddin Emon; Md Munsur Alam; Irin Akter; Saima Akhter; Anjuman Ara Sneha; Md Irtiza; Marufa Afroj; Arifa Munni; Masruba Hossen Chowdhury; Summiya Hossain
Journal:  Futur J Pharm Sci       Date:  2021-06-15

6.  Potential COVID-19 Drug Candidates Based on Diazinyl-Thiazol-Imine Moieties: Synthesis and Greener Pastures Biological Study.

Authors:  Sraa Abu-Melha; Mastoura Mohamed Edrees; Musa A Said; Sayed M Riyadh; Nadia S Al-Kaff; Sobhi M Gomha
Journal:  Molecules       Date:  2022-01-13       Impact factor: 4.411

7.  Structure-property relationship in thioxotriaza-spiro derivative: Crystal structure and molecular docking analysis against SARS-CoV-2 main protease.

Authors:  A H Udaya Kumar; K G Vindya; K J Pampa; K S Rangappa; N K Lokanath
Journal:  J Mol Struct       Date:  2021-10-17       Impact factor: 3.196

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.